GlassScriptPhysician profile
Preethi Gaddam
NPI 1669825642
$1,843.35
in general payments reported to CMS, 2019-2025
25 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $442 · 2024: $947 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $370.38 | 2023-2025 | |
| Abbvie INC. | $260.51 | 2023-2025 | |
| Novo Nordisk INC | $225.70 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $100.69 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $88.84 | 2025 | |
| Novartis Pharmaceuticals Corporation | $81.66 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.54 | 2023-2025 | Trintellix, Hyqvia |
| Hologic Sales and Service, LLC | $77.05 | 2023-2024 | Aptima |
| Corium, LLC | $67.22 | 2023-2024 | Azstarys |
| Grifols USA, LLC | $66.45 | 2024-2025 | Xembify |
| Viiv Healthcare Company | $55.77 | 2024 | Apretude |
| Alexion Pharmaceuticals, INC. | $53.71 | 2024 | Soliris |
| Lilly USA, LLC | $35.91 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Idorsia Pharmaceuticals US INC | $35.31 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $34.56 | 2023 | Xtampza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $33.72 | 2023-2024 | Adzenys Xr-Odt |
| Eisai INC. | $26.72 | 2024 | |
| Incyte Corporation | $25.77 | 2024 | Opzelura |
| Astrazeneca Pharmaceuticals LP | $20.47 | 2025 | Airsupra |
| Vbi Vaccine (Delaware) INC. | $19.51 | 2023 | Prehevbrio |
| Bausch Health US, LLC | $19.02 | 2023 | Aplenzin |
| Exeltis, USA INC. | $17.75 | 2024 | Slynd |
| Linus Health, INC. | $16.58 | 2024 | Core Cognitive Evaluation |
| Tris Pharma INC | $16.42 | 2023 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.09 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethi Gaddam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.